A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer. Continue Reading
Reportlinker.com announces that a new market research report is available in its catalogue: Global Pancreatic Cancer Drugs industry. Continue Reading
Robert Wood Johnson University Hospital Rahway (RWJ Rahway), a member of the Robert Wood Johnson Health System, has announced the selection of Emergency Medical Associates (EMA), one of the country’s premier emergency physician groups, to staff its Emergency Department. EMA began staffing the Emergency Department on April 1, 2010. Continue Reading
Royal Philips Electronics, in partnership with the American College of Cardiology, spotlight the growing need for minimally-invasive interventions to address a spectrum of cardiac conditions, such as structural and degenerative heart issues. The need to reduce invasive surgical interventions and complication rates is driving innovations in minimally invasive approaches. Continue Reading
In a case believed to be a United States first, the radiology team at Lucile Packard Children’s Hospital has used prenatal magnetic resonance imaging to detect an often-misdiagnosed genetic disease. Continue Reading
According to Millennium Research Group, the global authority on medical technology market intelligence, the recent launch of irrigated-tip catheters into the Japanese market will drive the ablation catheter market by a compound annual growth rate of approximately 15% through 2014. Continue Reading
TechniScan, Inc., a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that it has commenced phase two of its grant study at the University of California, San Diego (UCSD) Moores Cancer Center. Continue Reading
Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches. Continue Reading
